What is the share price of Alivus Life Sciences Ltd (ALIVUS) today?
The share price of ALIVUS as on 4th November 2026 is ₹1520.70. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Alivus Life Sciences Ltd (ALIVUS) share?
The past returns of Alivus Life Sciences Ltd (ALIVUS) share are- Past 1 week: 12.95%
- Past 1 month: 9.53%
- Past 3 months: 13.94%
- Past 6 months: 42.35%
- Past 1 year: 68.37%
- Past 3 years: 145.27%
- Past 5 years: 141.30%
What are the peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS)?
The peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS) include:What is the dividend yield % of Alivus Life Sciences Ltd (ALIVUS) share?
The current dividend yield of Alivus Life Sciences Ltd (ALIVUS) is 0.33.What is the market cap of Alivus Life Sciences Ltd (ALIVUS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd (ALIVUS) is ₹18699.63 Cr as of 4th November 2026.What is the 52 week high and low of Alivus Life Sciences Ltd (ALIVUS) share?
The 52-week high of Alivus Life Sciences Ltd (ALIVUS) is ₹1529 and the 52-week low is ₹819.What is the PE and PB ratio of Alivus Life Sciences Ltd (ALIVUS) stock?
The P/E (price-to-earnings) ratio of Alivus Life Sciences Ltd (ALIVUS) is 32.03. The P/B (price-to-book) ratio is 5.61.Which sector does Alivus Life Sciences Ltd (ALIVUS) belong to?
Alivus Life Sciences Ltd (ALIVUS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Alivus Life Sciences Ltd (ALIVUS) shares?
You can directly buy Alivus Life Sciences Ltd (ALIVUS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Alivus Life Sciences Ltd
ALIVUS Share Price
NSE₹1,520.702.66% (+39.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP
ALIVUS Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is underpriced but is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ALIVUS Performance & Key Metrics
ALIVUS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.92 | 5.61 | 0.33% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 43.84 | 5.87 | 0.49% |
100%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
ALIVUS Company Profile
Alivus Life Sciences Ltd develops and manufactures active pharmaceutical ingredients (APIs) and provides contract development and manufacturing services for chronic therapeutic areas.
PE Ratio
34.10
34.10
1Y Return
5.17%
5.17%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
81.89
81.89
1Y Return
31.45%
31.45%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
141.27
141.27
1Y Return
134.64%
134.64%
Buy Reco %
61.54
61.54
ZYDUSLIFE
PE Ratio
21.59
21.59
1Y Return
22.57%
22.57%
Buy Reco %
57.69
57.69
PE Ratio
27.28
27.28
1Y Return
13.56%
13.56%
Buy Reco %
67.74
67.74
ALIVUS Sentiment Analysis
ALIVUS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
ALIVUS Stock Summary · August 2026
Management described Q1 FY27 as a positive start to the year, with revenue up 6.4% year on year to INR 640 crores and profitability improving despite a sharp decline in the GPL business. The quarter was led by the broader portfolio, especially non-GPL revenue, which grew 26.5% on the back of new product launches and demand across geographies, while GPL fell 52.6% because of inventory rationalization that management said should not be read as a structural change. Margins also expanded, with gross margin reaching 60.2% and EBITDA margin rising to 36.6%, helped by mix, efficiency gains, and forex benefits. Management emphasised building a more diversified and sustainable growth base through new launches, CDMO execution, and ongoing R&D, with spending at 3.7% of sales and expected to move toward 4%. Near term, the company guided FY27 revenue growth of 10% to 12%, with the second half expected to carry more of the growth, EBITDA margins projected at 30% to 32%, and GPL expected to be roughly flat at worst for the year.
ALIVUS Stock Growth Drivers
ALIVUS Stock Growth Drivers
6Core revenue growth from diversified non-GPL and launch-led expansion
The company delivered a positive start to FY27 with revenue rising 6.4% year on year
Meaningful margin expansion and operating leverage
Profitability improved sharply in the quarter, reflecting better product mix, new launches, operational efficiencies, and
ALIVUS Stock Challenges
ALIVUS Stock Challenges
3Input Cost Inflation and War-Driven Margin Uncertainty
The company is facing rising raw material pressure, with cost inflation spreading from solvents to
Weak GPL Performance from Inventory Rationalization
GPL was a clear area of weakness in the quarter, with performance declining 52.6% year
ALIVUS Forecast
ALIVUS Forecasts
Price
Revenue
Earnings
ALIVUS Share Price Forecast
ALIVUS Share Price Forecast
2026
Current
₹1,522.00
Baseline
Forecast for Nov 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹1,522.00
Baseline
Forecast for Nov 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALIVUS Company Revenue Forecast
ALIVUS Company Revenue Forecast
2026
Current
₹2.61
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.61
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
ALIVUS Stock EPS (Earnings Per Share) Forecast
ALIVUS Stock EPS (Earnings Per Share) Forecast
2026
Current
₹46.03
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹46.03
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
ALIVUS
ALIVUS
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ALIVUS Income Statement
ALIVUS Income Statement
Quarterly Normal View
| Quarter | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | sep 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 594.11 | 515.41 | 652.30 | 659.63 | 610.83 | 602.70 | 686.82 | 711.90 | 662.82 | 701.90 | ||||||||||
Operating & Other expenses | 429.13 | 372.52 | 451.54 | 451.11 | 429.54 | 408.81 | 467.27 | 474.59 | 428.70 | 416.80 | ||||||||||
EBITDA | 164.98 | 142.89 | 200.76 | 208.52 | 181.29 | 193.89 | 219.55 | 237.31 | 234.12 | 285.10 | ||||||||||
| Depreciation/Amortization | 14.39 | 15.09 | 15.16 | 15.97 | 17.06 | 18.44 | 19.66 | 20.20 | 20.59 | 21.82 | ||||||||||
| PBIT | 150.59 | 127.80 | 185.60 | 192.55 | 164.23 | 175.45 | 199.89 | 217.11 | 213.53 | 263.28 | ||||||||||
| Interest & Other Items | 0.35 | 0.34 | 0.46 | 1.26 | 1.25 | 1.32 | 1.49 | 1.31 | 1.31 | 1.31 | ||||||||||
| PBT | 150.24 | 127.46 | 185.14 | 191.29 | 162.98 | 174.13 | 198.40 | 215.80 | 212.22 | 261.97 | ||||||||||
| Taxes & Other Items | 38.76 | 32.14 | 48.19 | 49.43 | 41.45 | 44.11 | 48.13 | 53.14 | 52.14 | 65.23 | ||||||||||
| Net Income | 111.48 | 95.32 | 136.95 | 141.86 | 121.53 | 130.02 | 150.27 | 162.66 | 160.08 | 196.74 | ||||||||||
| EPS | 9.10 | 7.78 | 11.18 | 11.57 | 9.91 | 10.60 | 12.25 | 13.23 | 13.04 | 16.02 |
ALIVUS Company Updates
FY 2027FY 2027
Investor Presentation
Oct 29PDF
Jul 30PDF
ALIVUS Stock Peers
ALIVUS Past Performance & Peer Comparison
ALIVUS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Alivus Life Sciences Ltd | 32.03 | 5.61 | 0.33% |
| Sun Pharmaceutical Industries Limited | 34.10 | 5.07 | 0.90% |
| Torrent Pharmaceuticals Ltd | 81.89 | 10.25 | 0.71% |
| Laurus Labs Ltd | 141.27 | 23.12 | 0.09% |
Compare valuation on ScreenerALIVUS Stock Price Comparison
Compare ALIVUS with any stock or ETFCompare ALIVUS with any stock or ETF
ALIVUS
ALIVUS Holdings
ALIVUS Shareholdings
ALIVUS Promoter Holdings Trend
ALIVUS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ALIVUS Institutional Holdings Trend
ALIVUS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ALIVUS Shareholding Pattern
ALIVUS Shareholding Pattern
ALIVUS Shareholding History
ALIVUS Shareholding History
Foreign Institutions
Mutual Funds Invested in ALIVUS
Mutual Funds Invested in ALIVUS
No mutual funds holding trends are available
Top 5 Mutual Funds holding Alivus Life Sciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6847% | Percentage of the fund’s portfolio invested in the stock 0.86% | Change in the portfolio weight of the stock over the last 3 months 0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/138 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9992% | Percentage of the fund’s portfolio invested in the stock 4.01% | Change in the portfolio weight of the stock over the last 3 months 0.16% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/27 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8240% | Percentage of the fund’s portfolio invested in the stock 2.05% | Change in the portfolio weight of the stock over the last 3 months 0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/62 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing ALIVUS stock
smallcases containing ALIVUS stock
Looks like this stock is not in any smallcase yet.
ALIVUS Events
ALIVUS Events
ALIVUS Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALIVUS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.34%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.37 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ALIVUS Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ALIVUS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.34%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.37 every year
ALIVUS Upcoming Dividends
ALIVUS Upcoming Dividends
No upcoming dividends are available
ALIVUS Past Dividends
ALIVUS Past Dividends
Cash Dividend
Ex DateEx DateSep 1, 2026
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 1, 2026
Cash Dividend
Ex DateEx DateSep 1, 2025
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 1, 2025
Cash Dividend
Ex DateEx DateOct 17, 2023
Interim
Interim | Div/Share: ₹22.50
Dividend/Share
₹22.50
Ex DateEx Date
Oct 17, 2023
Cash Dividend
Ex DateEx DateMar 24, 2023
Interim
Interim | Div/Share: ₹21.00
Dividend/Share
₹21.00
Ex DateEx Date
Mar 24, 2023
Cash Dividend
Ex DateEx DateSep 15, 2022
Final
Final | Div/Share: ₹10.50
Dividend/Share
₹10.50
Ex DateEx Date
Sep 15, 2022
ALIVUS Stock News & Opinions
ALIVUS Stock News & Opinions
Articles & Videos
Corporate
Corporate
Alivus Life Sciences’ board approved allotment of shares to employees exercising stock optionsAlivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced that its board of directors approved the allotment of 1,95,833 equity shares with a face value of Rs 2 each to eligible employees who exercised stock options under the ‘Employee Stock Option Scheme, 2021’, increasing the company's paid-up share capital from 12,27,71,448 equity shares aggregating to Rs 24,55,42,896 to 12,29,67,281 equity shares aggregating to Rs 24,59,34,562.
6 days agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences to review financial results at board meeting October 29, 2026Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, will hold a board meeting on Thursday, October 29, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, and has closed the trading window for its designated persons from October 1, 2026, to October 31, 2026, in accordance with SEBI regulations.
1 week agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences to review financial results at board meeting October 29, 2026Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, will hold a board meeting on Thursday, October 29, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, and has closed the trading window for its designated persons from October 1, 2026, to October 31, 2026, in accordance with SEBI regulations.
2 weeks agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma for approximately Rs 9.12 croresAlivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced that its board approved a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately Rs 9.12 crores, subject to adjustment as per the share purchase agreement. IQGEN-X Pharma Private Limited, incorporated in October 2016, reported a turnover of Rs 348 lacs for the financial year ended March 31, 2026, and is engaged in the business of formulation development for regulated and semi-regulated markets, with the acquisition expected to provide Alivus Life Sciences a wider spectrum to offer end-to-end solutions in the API and CDMO space.
2 months agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences recommends Rs 5.00 per share dividend at September 2026 meetingAlivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, will hold its Fifteenth Annual General Meeting on September 8, 2026, at 3:00 p.m. IST, and the board of directors has recommended a final dividend of Rs 5.00 per equity share of Rs 2 each for the financial year ended March 31, 2026, with a record date of September 1, 2026, and payment expected to be made on or after September 11, 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Alivus Life Sciences standalone net profit rises 31.71% in the June 2026 quarterNet profit of Alivus Life Sciences rose 31.71% to Rs 160.08 crore in the quarter ended June 2026 as against Rs 121.54 crore during the previous quarter ended June 2025. Sales rose 6.41% to Rs 640.41 crore in the quarter ended June 2026 as against Rs 601.85 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales640.41601.85 6 OPM %33.0628.63 - PBDT232.81180.05 29 PBT212.22162.99 30 NP160.08121.54 32 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences’ board approved allotment of shares to employees exercising stock optionsAlivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced that its board of directors approved the allotment of 32,000 equity shares of Rs 2 face value each to eligible employees who exercised stock options under the ‘Employee Stock Option Scheme, 2021’, increasing the company's paid-up share capital from 12,27,39,448 equity shares aggregating to Rs 24,54,78,896 to 12,27,71,448 equity shares aggregating to Rs 24,55,42,896.
3 months agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences reports Rs 1,601 million net profit, revenue up 6.4% year-over-yearAlivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced a net profit after tax of Rs 1,601 million for the first quarter ended June 30, 2026, a 31.8% year-over-year increase, alongside revenue from operations of Rs 6,404 million, up 6.4% year-over-year, driven by a 26.5% year-over-year growth in its non-GPL business. The company reported earnings before interest, taxes, depreciation, and amortization of Rs 2,341 million, a 29.1% year-over-year increase, with margins at 36.6%, and held cash and cash equivalents of Rs 8,802 million as of June 30, 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences to table resultsAlivus Life Sciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Alivus Life Sciences to discuss resultsAlivus Life Sciences will hold a meeting of the Board of Directors of the Company on 30 July 2026.
3 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 6.73%, vs industry avg of 10.72%
Over the last 5 years, market share decreased from 0.62% to 0.51%
Over the last 5 years, net income has grown at a yearly rate of 9.93%, vs industry avg of 10.43%